Literature DB >> 21149658

Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial.

Juanita Mary Crook1, Alfonso Gomez-Iturriaga, Kris Wallace, Clement Ma, Sharon Fung, Shabbir Alibhai, Michael Jewett, Neil Fleshner.   

Abstract

PURPOSE: The American College of Surgeons Oncology Group phase III Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial comparing radical prostatectomy (RP) and brachytherapy (BT) closed after 2 years due to poor accrual. We report health-related quality of life (HRQOL) at a mean of 5.3 years for 168 trial-eligible men who either chose or were randomly assigned to RP or BT following a multidisciplinary educational session. PATIENTS AND METHODS: After initial lack of accrual, a multidisciplinary educational session was introduced for eligible patients. In all, 263 men attended 47 sessions. Of those, 34 consented to random assignment, 62 chose RP, and 94 chose BT. Five years later, these 190 men underwent HRQOL evaluation by using the cancer-specific 50-item Expanded Prostate Cancer Index Composite, the Short Form 12 Physical Component Score, and Short Form 12 Mental Component Score. Response rate was 88.4%. The Wilcoxon rank sum test was used to compare summary scores between the two interventions.
RESULTS: Of 168 survey responders, 60.7% had BT (9.5% randomly assigned) and 39.3% had RP (9.5% randomly assigned). Median age was 61.4 years for BT and 59.4 for RP (P = .05). Median follow-up was 5.2 years (range, 3.2 to 6.5 years). For BT versus RP, there was no difference in bowel or hormonal domains, but men treated with BT scored better in urinary (91.8 v 88.1; P = .02) and sexual (52.5 v 39.2; P = .001) domains, and in patient satisfaction (93.6 v 76.9; P < .001).
CONCLUSION: Although treatment allocation was random in only 19%, all patients received identical information in a multidisciplinary setting before selecting RP, BT, or random assignment. HRQOL evaluated 3.2 to 6.5 years after treatment showed an advantage for BT in urinary and sexual domains and in patient satisfaction.

Entities:  

Mesh:

Year:  2010        PMID: 21149658     DOI: 10.1200/JCO.2010.31.7305

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  49 in total

1.  Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer.

Authors:  George Rodrigues; Xiaomei Yao; D Andrew Loblaw; Michael Brundage; Joseph L Chin
Journal:  Can Urol Assoc J       Date:  2013 May-Jun       Impact factor: 1.862

2.  Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing.

Authors:  Nikhil G Thaker; Thomas J Pugh; Usama Mahmood; Seungtaek Choi; Tracy E Spinks; Neil E Martin; Terence T Sio; Rajat J Kudchadker; Robert S Kaplan; Deborah A Kuban; David A Swanson; Peter F Orio; Michael J Zelefsky; Brett W Cox; Louis Potters; Thomas A Buchholz; Thomas W Feeley; Steven J Frank
Journal:  Brachytherapy       Date:  2016-02-23       Impact factor: 2.362

3.  Prostate capsule sparing versus nerve sparing radical cystectomy for bladder cancer: results of a randomized, controlled trial.

Authors:  Bruce L Jacobs; Stephanie Daignault; Cheryl T Lee; Khaled S Hafez; Jeffrey S Montgomery; James E Montie; Jean E Humrich; Brent K Hollenbeck; David P Wood; Alon Z Weizer
Journal:  J Urol       Date:  2014-07-24       Impact factor: 7.450

4.  Five-year potency preservation after iodine-125 prostate brachytherapy.

Authors:  Shuichi Nishimura; Atsunori Yorozu; Toshio Ohashi; Masanori Sakayori; Yasuto Yagi; Toru Nishiyama; Shiro Saito; Yutaka Shiraishi; Kayo Yoshida; Kazuhito Toya; Naoyuki Shigematsu
Journal:  Int J Clin Oncol       Date:  2013-10-31       Impact factor: 3.402

5.  A new dawn in prostate cancer management: Do we have the trials to support it?

Authors:  D Andrew Loblaw
Journal:  Can Urol Assoc J       Date:  2011-06       Impact factor: 1.862

6.  Prospective quality-of-life outcomes for low-risk prostate cancer: Active surveillance versus radical prostatectomy.

Authors:  Claudio Jeldres; Jennifer Cullen; Lauren M Hurwitz; Erika M Wolff; Katherine E Levie; Katherine Odem-Davis; Richard B Johnston; Khanh N Pham; Inger L Rosner; Timothy C Brand; James O L'Esperance; Joseph R Sterbis; Ruth Etzioni; Christopher R Porter
Journal:  Cancer       Date:  2015-04-06       Impact factor: 6.860

Review 7.  High dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancer.

Authors:  A Challapalli; E Jones; C Harvey; G O Hellawell; S A Mangar
Journal:  Br J Radiol       Date:  2012-11       Impact factor: 3.039

8.  5-alpha reductase inhibitors in patients on active surveillance: do the benefits outweigh the risk?

Authors:  Ghazi Al Edwan; Neil Fleshner
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 3.092

9.  Canadian prostate brachytherapy in 2012.

Authors:  Mira Keyes; Juanita Crook; W James Morris; Gerard Morton; Tom Pickles; Nawaid Usmani; Eric Vigneault
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

10.  Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy.

Authors:  David S Hong; Goldy C George; Eucharia C Iwuanyanwu; Bahareh Tavana; Gerald S Falchook; Sarina A Piha-Paul; Jennifer J Wheler; Reena H Mistry; Xiudong Lei; Razelle Kurzrock
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-02       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.